HOPE-3 Phase 3 Study Topline Data Call Capricor Therapeutics, Inc. Nasdaq: CAPR December 3, 2025 1 Forward Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions wit ...